Site icon pharmaceutical daily

Global Facial Injectable Market (2020 to 2025) – Featuring Sanofi, Sinclair Pharma and Suneva Medical Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Facial Injectable Market – Forecasts from 2020 to 2025” report has been added to ResearchAndMarkets.com’s offering.

The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness about appearance along with the increasing pool of geriatric population is the primary driver that is estimated to catapult the facial injectable market to new heights during the forecast period.

Moreover, the increasing shift towards minimally invasive procedures and continuous developers in glacial rejuvenation is expected to further augment the growth for the same market. Additionally, the rising awareness regarding the accessibility of various products and procedures, which has stemmed due to the increasing number of players entering the facial injectables space across the globe is forecasted to further add to the surge that the market is expected to witness. Besides, the importance of skincare has gained quite a momentum as exemplified by the fact that 71,800 jobs in 2018 were held by skincare specialists, 47% of which were employed by personal care services in the United States. Additionally, the projected employment in 2028 is estimated at 79,600 [Source: U.S. Bureau of Labor Statistics].

Further, individualistic value-driven rational has superseded the generic mob mentality of the yesteryears which incentivizes today’s consumers to look for products that more oriented to themselves. Further, this interest has also fueled investments in various research studies like that of DREAM (Dysport Real-world Evaluation and Measured satisfaction study) carried out by Galderma after which in May 2020, it announced 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients believed the result of the treatment looked natural. Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Companies Mentioned

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.4. Industry Value Chain Analysis

5. Facial Injectable Market Analysis, By Type

5.1. Introduction

5.2. Botulinum Toxin

5.3. Collagen

5.4. Hyaluronic Acid

5.5. Particle & Polymer Fillers (PPF)

5.5.1. Calcium Hydroxyapatite

5.5.2. Poly-l-Lactic Acid

5.5.3. Polymethylmethacrylate

6. Facial Injectable Market Analysis, By Generation

6.1. Introduction

6.2. Gen X

6.3. Boomer

6.4. Millennials

7. Facial Injectable Market Analysis, By End-User

7.1. Introduction

7.2. Dermatology & Beauty Clinics

7.3. Hospitals

7.4. Research Institutes

8. Facial Injectable Market Analysis, by Geography

8.1. Introduction

8.2. North America

8.3. South America

8.4. Europe

8.5. The Middle East and Africa

8.6. Asia Pacific

9. Competitive Environment and Analysis

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/2uavyi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version